Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

British Journal of Cancer

Volumn 80, Issue 1-2, 1999, Pages 286-294

  De Witte, J H ^a   Sweep, C G J ^a   Klijn, J G M ^b   Grebenschikov, N ^a   Peters, H A ^b   Look, M P ^b   Van Tienoven, Th H ^a   Heuvel, J J T M ^a   Bolt De Vries, J ^b   Benraad, Th J ^a   Foekens, J A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Cytosol; ELISA; Prognostic impact; Tissue type plasminogen activator; tPA:PAI 1 complex

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROID RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032953135     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690353     Document Type: Article

References (35)

1. Benraad ThJ, Geurts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuvel JJTM, De Witte JH, Foekens JA, Leake RE, Brünner N and Sweep CGJ (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A: 1371-1381
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
3. Butler WB, Kirkland WL, Gargala TL, Goran N, Kelsey WH and Berlinsky PJ (1983) Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7). Cancer Res 43: 1637-1641
4. Conese M and Blasi F (1995) Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanisms and regulation. Biol Chem Hoppe-Seyler 376: 143-155
5. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
6. De Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Dooijewaard G, Van den Ingh HF and Lamers BHW (1988) Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 48: 4520-4524
7. De Witte JH, Sweep CGJ, Klijn J, Grebenschikov N, Peters H, Look M, Van Tienoven ThH, Van Putten W, Benraad ThJ and Foekens JA (1998) Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer (accepted for publication)
8. Dudani AK and Ganz PR (1996) Endothelial cell surface actin serves as a binding site for plasminogen, tissue-type plasminogen activator and lipoprotein(a). Br J Haematol 95: 168-178
9. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
10. Duffy MJ, O'Grady P, Simon J, Rose M and Lijnen HR (1986) Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. J Natl Cancer Inst 77: 621-623
11. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HR (1988) Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348-1349
12. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N and Duffy MJ (1997) Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 76: 622-627
13. Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW and Andreasen PA (1997) Type-1 plasminogen-activator inhibitor; conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 248: 775-785
14. EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC workshop, held on 16-17 March 1979, in The Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515
15. Foekens JA, Portengen H, Van Putten WLJ, Peters HA, Krijnen HLJM, Alexieva-Figusch J and Klijn JGM (1989) Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49: 5823-5828
16. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F and Benraad T (1997) A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 12: 6-14
17. Grøndahl-Hansen J, Bach F and Munckholm-Larsen P (1990) Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay. Br J Cancer 61: 412-414
18. Hansson P-O, Eriksson H, Eriksson E, Jagenburg R, Lukes P and Risberg B (1994) Can laboratory testing improve screening strategies for deep vein thrombosis at an emergency unit? J Int Med 235: 143-151
19. Hekman CM and Loskutoff DJ (1985) Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260: 11581-11587
20. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
21. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type-1 inhibitor in breast cancer. Semin Thromb Hemostas 17: 303-312
22. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481
23. Layer GT, Burnand KG, Gaffney PJ, Cederholm-Williams SA, Mahmoud M, Houlbrook S and Pattison M (1987) Tissue plasminogen activators in breast cancer. Thromb Res 45: 601-607
24. Levin EG, Santell L and Osborn KG (1997) The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. J Cell Sci 110: 139-148
25. Maser RE, Ellis D, Erbey JR and Orchard TJ (1997) Do tissue plasminogen activator-plasminogen activator inhibitor-I complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 11: 243-249
26. Mignatti P and Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
27. Mira-Y-Lopez R and Ossowski L (1987) Hormonal modulation of plasminogen activator; an approach to predicting human breast tumor responsiveness. Cancer Res 47: 3558-3564
28. Needham GK, Nicholson S, Angus B, Farndon JR and Harris AL (1988) Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res 48: 6603-6607
29. Niwano H, Takahashi H, Tatewaki W, Wada K, Seki Y and Shibata A (1992) Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Blood Coagul Fibrinol 3: 389-393
30. Rella C, Coviello M, Quaranta M and Paradiso A (1993) Tissue type plasminogen activator as a marker of functional steroid receptors in human breast cancer. Thromb Res 69: 209-220
31. Rijken DC (1995) Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillière's Clin Haematol 8: 291-312
32. Schmitt M, Jänicke F and Graeff H (1990) Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinol 1: 695-702
33. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296
34. Yamashita J-I, Ogawa M, Yamashita S, Nakashima Y, Saishoji T, Nomura K, Inada K and Kawano I (1993) Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 68: 524-529
35. Yamashita J-I, Ogawa M and Sakai K (1995) Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117: 601-608